Epigenetics in Prostate Cancer: Biologic and Clinical Relevance

Slides:

Advertisements

Similar presentations

Volume 61, Issue 5, Pages (May 2012)

Advertisements

Volume 68, Issue 6, Pages (December 2015)

Volume 46, Issue 6, Pages (December 2004)

The PSA Era is not Over for Prostate Cancer

Volume 50, Issue 1, Pages (July 2006)

Volume 52, Issue 1, Pages (July 2007)

Volume 65, Issue 6, Pages (June 2014)

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Volume 44, Issue 6, Pages (December 2003)

Molecular and serum markers in hepatocellular carcinoma: Predictive tools for prognosis and recurrence Ashish Singhal, Muralidharan Jayaraman, Danny.

Volume 61, Issue 6, Pages (June 2012)

Volume 53, Issue 4, Pages (April 2008)

The Role of Tobacco Smoke in Bladder and Kidney Carcinogenesis: A Comparison of Exposures and Meta-analysis of Incidence and Mortality Risks Marcus G.

Volume 71, Issue 2, Pages (February 2017)

Volume 49, Issue 2, Pages (February 2006)

Volume 60, Issue 1, Pages (July 2011)

Volume 61, Issue 5, Pages (May 2012)

Volume 53, Issue 5, Pages (May 2008)

Volume 64, Issue 4, Pages (October 2013)

Volume 69, Issue 1, Pages (January 2016)

Volume 51, Issue 4, Pages (April 2007)

Volume 51, Issue 3, Pages (March 2007)

Volume 65, Issue 6, Pages (June 2014)

MicroRNA in Prostate, Bladder, and Kidney Cancer: A Systematic Review

Volume 73, Issue 5, Pages (May 2018)

Prostate Cancer Epidemic in Sight?

Volume 58, Issue 1, Pages (July 2010)

Re: Marcus G. Cumberbatch, Matteo Rota, James W. F

Volume 68, Issue 4, Pages (October 2015)

Volume 63, Issue 1, Pages (January 2013)

Volume 63, Issue 4, Pages e53-e56 (April 2013)

Nomograms for Bladder Cancer

The Importance of Transurethral Resection in Managing Patients With Urothelial Cancer in the Bladder: Proposal for a Transurethral Resection of Bladder.

Volume 54, Issue 4, Pages (October 2008)

The Potential of MicroRNAs as Prostate Cancer Biomarkers

Ute Ganswindt, Arnulf Stenzl, Michael Bamberg, Claus Belka

Volume 53, Issue 4, Pages (April 2008)

Prostate Cancer Detection: A View of the Future

Volume 67, Issue 3, Pages (March 2015)

Treatment of Symptomatic Benign Prostatic Hyperplasia: Current and Future Clinical Practice in Europe – What is Really Happening? Bob Djavan European.

Shaheen Alanee, Kasmintan Schrader, Kenneth Offit European Urology

The Mutational Landscape of Prostate Cancer

Volume 73, Issue 4, Pages (April 2018)

Volume 66, Issue 6, Pages (December 2014)

Prostate Cancer Epidemic in Sight?

The PSA Era is not Over for Prostate Cancer

Volume 61, Issue 5, Pages (May 2012)

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Re: Yves Allorya, Willemien Beukers, Ana Sagrera, et al

Volume 68, Issue 6, Pages (December 2015)

Volume 61, Issue 6, Pages (June 2012)

Volume 53, Issue 4, Pages (April 2008)

Volume 56, Issue 1, Pages (July 2009)

Shifting Paradigms for High-grade Prostatic Intraepithelial Neoplasia

Volume 67, Issue 1, Pages 7-10 (January 2015)

Is It Necessary to Detect All Prostate Cancers in Men with Serum PSA Levels

Volume 50, Issue 5, Pages (November 2006)

Re: Christine McKillop

CyberKnife in the Treatment of Prostate Cancer: A Revolutionary System

Volume 55, Issue 3, Pages (March 2009)

Testicular Cancer Variations in Time and Space in Europe

Volume 53, Issue 1, Pages (January 2008)

Volume 59, Issue 4, Pages (April 2011)

European Urology is “Your” Journal

Improving Outcomes in Prostate Cancer: Time to Tackle Bone Disorders

Psychotherapeutic Interventions Targeting Prostate Cancer Patients: A Systematic Review of the Literature Liliana Vartolomei, Shahrokh F. Shariat, Mihai.

Volume 54, Issue 1, Pages (July 2008)

Volume 53, Issue 2, Pages (February 2008)

Volume 51, Issue 5, Pages (May 2007)

How to Treat a Patient with T1 High-grade Disease and No Tumour on Repeat Transurethral Resection of the Bladder? Shahrokh Shariat, Paolo Gontero, James.

Presentation transcript:

Epigenetics in Prostate Cancer: Biologic and Clinical Relevance Carmen Jerónimo, Patrick J. Bastian, Anders Bjartell, Giuseppina M. Carbone, James W.F. Catto, Susan J. Clark, Rui Henrique, William G. Nelson, Shahrokh F. Shariat European Urology Volume 60, Issue 4, Pages 753-766 (October 2011) DOI: 10.1016/j.eururo.2011.06.035 Copyright © 2011 European Association of Urology Terms and Conditions

Fig. 1 Schematic overview of the crosstalk between ETS–polycomb group proteins and ETS–miRNA in prostate cancer. ESC=embryonic stem cell; AR=androgen receptor European Urology 2011 60, 753-766DOI: (10.1016/j.eururo.2011.06.035) Copyright © 2011 European Association of Urology Terms and Conditions

Fig. 2 Epigenetic biomarkers in prostate cancer (PCa) management. From the published data, specific sets of informative biomarkers were chosen for cancer detection (EpiTest 1), as ancillary tools to histopathologic observation (EpiTest 2), pretherapeutic prediction of prognosis and tumor aggressiveness (EpiTest 3), and prediction of recurrence and progression following radical prostatectomy (EpiTest 4). Meth refers to quantitative DNA methylation analysis; histone modifications and expression of histone modifiers are assessed by immunohistochemistry; microRNA expression is assessed by quantitative reverse-transcriptase polymerase chain reaction. PCa=prostate cancer European Urology 2011 60, 753-766DOI: (10.1016/j.eururo.2011.06.035) Copyright © 2011 European Association of Urology Terms and Conditions